Navigation Links
Horizon Technology Finance Closes $2 Million Venture Loan Facility with New Haven Pharmaceuticals
Date:4/25/2013

FARMINGTON, Conn. and GUILFORD, Conn., April 25, 2013 /PRNewswire/ -- Horizon Technology Finance Corporation (Nasdaq: HRZN) ("Horizon"), a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and clean-tech industries, today announced it has closed a $2 million venture loan facility with New Haven Pharmaceuticals, Inc. ("NHP"), a developer of prescription pharmaceuticals that utilize currently marketed drugs or active pharmaceutical ingredients generally recognized as safe for use in therapeutic applications. The proceeds of the venture loan facility will be used for working capital purposes.

"We are pleased to provide NHP with a venture loan facility which will support its development of proprietary prescription pharmaceuticals," stated Gerald A. Michaud , President of Horizon. "NHP continues to achieve important strides in developing products for patients with a higher risk for secondary strokes or acute cardiac events. Based on the company's impressive product pipeline and experienced, well-respected management team, NHP represents a strong addition to Horizon's high-quality investment portfolio."

"Horizon's $2 million venture loan facility provides NHP with the right capital structure and the timely liquidity to continue to execute our product development and FDA registration plans," stated Patrick P. Fourteau, NHP's President & CEO. Harry H. Penner, Jr. , NHP's Executive Chairman, added, "The responsiveness and flexibility of the Horizon team resulted in a seamless process from initial contact to funding and a very positive business experience. It's gratifying to have Horizon, a Connecticut-based company like our own, as a financial partner."

About Horizon Technology Finance
Horizon Technology Finance Corporation is a business development company that provides secured loans to development-stage companies backed by established venture capital and private equity firms within the technology, life science, healthcare information and services, and clean-tech industries. The investment objective of Horizon Technology Finance is to maximize total risk-adjusted returns by generating current income from a portfolio of directly originated secured loans as well as capital appreciation from warrants to purchase the equity of portfolio companies. Headquartered in Farmington, Connecticut, with regional offices in Walnut Creek, California and Reston, Virginia, the Company is externally managed by its investment advisor, Horizon Technology Finance Management LLC. Horizon's common stock trades on the NASDAQ Global Select Market under the ticker symbol, "HRZN." In addition, the Company's 7.375% Senior Notes due 2019 trade on the New York Stock Exchange under the ticker symbol "HTF." To learn more, please visit www.horizontechnologyfinancecorp.com.

About New Haven Pharmaceuticals
New Haven Pharmaceuticals Inc. (NHP) is a specialty pharmaceutical company developing proprietary prescription drug products based on proprietary controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience. For more information on NHP, please visit www.newhavenpharma.com, or contact Harry H. Penner, Jr. , Executive Chairman at (203) 676-3676, or email at hpenner@newhavenpharma.com.

Forward-Looking Statements
Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.Contact: Horizon Technology Finance CorporationInvestor Relations and Media Contacts:Christopher M. MathieuThe IGB Group Chief Financial OfficerMichael Cimini / Leon Berman(860) 676-8653(212) 477-8261 / (212) 477-8438chris@horizontechfinance.commcimini@igbir.com / lberman@igbir.com


'/>"/>
SOURCE Horizon Technology Finance Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Future Horizons in the Global Orthopedics Market
2. Horizon Pharma Announces Issuance of U.S. Patent Covering RAYOS (delayed-release prednisone)
3. 110+ Health Care Providers Announce Plans To Use Advanced Medical Records Technology To Improve Care For Thousands Of Denver-Area Patients
4. Memorial Hospital of Lafayette County Boosts Patient Safety with Expanded Use of Capnography Technology
5. TriMix Laboratories Announces New TriMix-gel Partnership with KRS Global Biotechnology
6. Endexx to attend NAMA Spring Expo for Medical Marijuana Technology Solutions
7. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
8. iBio Passes Commercial Technology Transfer Milestone
9. Sanovas Launches Next Generation Surgical Imaging Technology
10. George Rosenkranz to Receive 2013 Biotechnology Heritage Award
11. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... RadSite™, ... serve on its Accreditation and Standards Committees to support the organization’s quality ... image quality and reducing patient radiation dose,” reports Eliot Siegel, MD, RadSite’s ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
(Date:4/21/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, wrote ... global crisis with solution to peace plan. Yisrayl says war has never brought peace and ... by the Creator Himself. , Yisrayl says war drums are beating all over the ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... news for older shoulder replacement patients; post-operative recovery just might be even better ... of patients presenting with osteoarthritis following surgery: 262 patients under 65 and 103 ...
Breaking Medicine News(10 mins):